Chelsey Yang

Education

M.B.A., The University of Chicago Booth School of Business; B.A., economics and mathematics, Mount Holyoke College

Summary of Experience

Ms. Yang specializes in health economics and outcomes research (HEOR) and real-world evidence (RWE) studies. She has led the design and implementation of complex economic modeling and RWE solutions to support pharmaceutical clients in regulatory submissions, health technology assessments (HTAs), and clinical and economic evidence generation. Her research covers a variety of study types, including cost-effectiveness analyses, budget impact analyses, treatment pattern and outcome analyses, burden-of-illness analyses, systematic literature reviews, and indirect treatment comparisons. In her work, Ms. Yang uses data from large retrospective databases, medical chart reviews, disease registries, clinical trials, surveys, and qualitative interviews. She has experience with a broad range of therapeutic areas, including hematology, oncology, cardiovascular disease, rheumatology, dermatology, gastroenterology, rare diseases, and vaccines. Ms. Yang’s work has been presented at clinical and economic research conferences and published in various peer-reviewed journals.

• Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

  Advances in Therapy, 2023
  2023

  Huang M, Fasching PA, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, Cappoen N, O'Shaughnessy J

  HEOR, Epidemiology & Market Access
• Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review

  Current Medical Research and Opinion, Opin 2016 01; 32(4): 741-747
  2016

  Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E